For this position, the recruiting organisation is the University of Zurich (UZH) in Zurich, Switzerland. The selected candidate will be employed by UZH and become part of the POLARIS consortium, with academic supervision and genome-editing expertise provided by Prof. Gerald Schwank at the Institute of Pharmacology and Toxicology.

Keywords

#Lipid nanoparticles (LNPs) · #mRNA delivery · #Genetic therapies · #Leukodystrophies · #Preclinical mouse models

Institute of Pharmacology and Toxicology, University of Zurich

  • Switzerland

The Institute of Pharmacology and Toxicology at the University of Zurich conducts research at the interface of molecular medicine, pharmacology and therapeutic innovation. The Schwank laboratory develops and applies genome-editing technologies to understand and treat genetic diseases, with a focus on precise and durable therapeutic genome engineering.

Prof. Gerald Schwank’s team develops programmable genome-editing systems and delivery strategies for therapeutic applications. By combining expertise in genome-editor engineering, molecular biology and translational model systems, the team aims to advance safe and effective genetic medicines for severe inherited diseases.

PhD project description

This doctoral project focuses on the in vitro and in vivo preclinical assessment of genetic therapies for leukodystrophies. You will investigate lipid nanoparticle (LNP)-based approaches for delivering therapeutic nucleic acids, such as mRNA, in cellular and animal models.

The research follows a translational pathway towards clinical application. You will investigate the functionality, biodistribution and cellular tropism of LNP-mRNA delivery systems and evaluate their therapeutic efficacy in mouse models of leukodystrophies.

A planned secondment at the University of York will provide experience of working with patient-family organisations and exposure to additional disease models.

Eligibility criteria

Important, strict eligibility criteria according to MARIE SKLODOWSKA CURIE programs apply to applicants:

  1. You must not already hold a doctoral degree.
  2. At the time of the application deadline, you must have a Master’s degree and must not have resided or carried out your main activity (work, studies, etc.) in the UK for more than 12 months in the three years prior to the contract start date.
  3. You will participate in the network-wide training programme of POLARIS, which includes (international) training activities and planned secondments with POLARIS partner organizations throughout the EU.

Requirements and candidate profile

We are looking for a motivated candidate with a Master’s degree in molecular biology, biomedical sciences, biotechnology, genetics, pharmacology or a related life-science discipline. You have a strong interest in genome editing, therapeutic innovation, translational research and rare neurological diseases.

Experience with molecular cloning, genome-editing technologies, cell culture, gene-delivery approaches or related experimental techniques is considered an advantage. Interest in developing precise and durable therapeutic strategies for inherited disorders is highly relevant for this position. Experience with disease modelling, stem cell systems, sequencing-based readouts or translational preclinical research would also be valuable.

You work accurately and reproducibly, have strong analytical and communication skills, and are able to collaborate effectively in an interdisciplinary and international research environment.

Terms of employment

  • A contract for a total of 3 years;
  • Salary, mobility allowance and benefits according to the applicable MSCA Doctoral Network and host-organisation rules. More detailed information about the salary will follow;
  • Embedding in the international POLARIS doctoral training network;
  • Access to network-wide training activities, secondments and transferable-skills development;
  • A challenging and translational research project at the interface of in vivo neuroscience, rare disease biology and preclinical genetic therapy development;
  • A collaborative and entrepreneurial working environment;
  • An open and supportive team culture with opportunities for scientific and professional development

Recruitment procedure and application

Applications for the doctoral positions have now closed. The selection process is currently ongoing, and applications are being reviewed by the recruiting institutions.

POLARIS is now moving into the next phase of its doctoral programme, which will bring together a new cohort of researchers working across disciplines and sectors to advance translational research in leukodystrophies.